Profile: Clovis Oncology Inc (CLVS.OQ)
Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).
Rubraca is an oral and small molecule inhibitor of PARP1, PARP2 and PARP3. It is approved as monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an Food and Drug Administration (FDA)-approved companion diagnostic for Rubraca. It is also approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Rucaparib is also being developed in patients with mutant BRCA tumors and other DNA repair deficiencies beyond BRCA, which are referred to as homologous recombination deficiencies (HRD).
The Company competes with AstraZeneca UK Limited, AstraZeneca and Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., BeiGene, Ltd., Checkpoint Therapeutics Inc., Janssen Biotech, Inc., Novartis Pharmaceuticals Corporation and AbbVie Inc.
Clovis Oncology Inc
5500 Flatiron Pkwy Unit 100
BOULDER CO 80301-2834